Declan Murphy, MB, BCh, on Rate of Equivocal Findings on PSMA PET/CT in Patients With Prostate Cancer


Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.

Professor Declan Murphy, MB, BCh, of the Peter MacCallum Cancer Centre, spoke with CancerNetwork® about the rate of equivocal findings in the proPSMA study for patients with prostate cancer undergoing prostate-specific membrane antigen (PSMA) PET/CT imaging.


At the SUO [Society of Urologic Oncology 21st Annual] Meeting, I was asked to talk about PSMA for upstaging because, traditionally, that’s what people see with PSMA PET/CT. You do a scan in a patient and you don’t see any cancer outside the prostate. Then you cross over and have a PSMA PET/CT and you see additional lymph nodes or even distant metastases. Traditionally, we think it’s picking up stuff that conventional imaging does not, but there’s an additional factor which is why we emphasize that its accuracy, not especially upstaging, that matters. We show in proPSMA a secondary end point [of] the rate of equivocal findings, and in conventional imaging, 23% of our patients had equivocal findings on CT or bone scans.

What does that mean? This is all too familiar territory for anyone out there looking after [patients with] prostate cancer. You do a CT or a bone scan and the report comes back saying equivocal bone lesion in the rib or [other area]. We see that in 1 in 4 patients, and so what that leads to, of course, is uncertainty which needs to be resolved. Then patients traditionally will go on and have novel imaging or an MRI scan or even a biopsy to clarify that. That’s a high rate of equivocal findings, whereas in the PSMA PET/CT arm we see equivocal findings in only about 6% or 7% of patients. As a secondary end point, we think this is very important. We understand equivocal findings are very common, proPSMA confirmed that, and this creates uncertainty and leads to further investigation. This needed to be clarified, the rate of equivocal findings, and it was much better [in the trial discussed herein].

Related Videos
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Expert on prostate cancer
Expert on prostate cancer
Experts on prostate cancer
Expert on prostate cancer
Expert on prostate cancer
Related Content